Edgewise Therapeutics clinical trials we track

Check company identity source

Phase 2 6 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of adverse events in those treated with sevasemten or placebo Measure: Severity of adverse events in those treated with sevasemten or placebo Measure: Change from Baseline in serum Creatine Kinase Measure: Change from Baseline in the North Star Ambulatory Assessment scale. After: Measure: Number of treatment emergent adverse events in those treated with sevasemten or placebo Measure: Severity of treatment emergent adverse events in those treated with sevasemten or placebo Measure: Change from Baseline in serum Creatine Kinase Measure: Change from Baseline in total North Star Ambulatory Assessment score.

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Sep 2026. After: 7 Sep 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source